Exposure and virologic outcomes of dolutegravir combined with ritonavir boosted darunavir in treatment-naïve individuals enrolled in the Netherlands Cohort Study on Acute HIV infection (NOVA)

•Dolutegravir (DTG) and darunavir/ritonavir (DRV/r) are potent and favourable options for treatment of human immunodeficiency virus infection.•The glucuronidation metabolic ratio of DTG increased when co-administered with DRV/r, probably due to ritonavir.•The effect of DRV/r co-administration on total and trough exposure of twice-daily DTG was investigated.•DRV/r and DTG performance during the highly viraemic phase of acute HIV infection was studied.